ME1 18 October 2023Melodiol delivers another record quarter with...

ME1
18 October 2023
Melodiol delivers another record quarter with ~$7.5m in revenue
generated during Q3 FY/CY23, up 265% on the PCP
Highlights:
• Circa $7.5m in unaudited revenue achieved across the Melodiol Group of companies in Q3 FY23 – a
265% increase on the PCP (Q3 FY22: $2.05m), and a 58% rise on last quarter (Q2 FY23: $4.74m)
• Q3 FY23 revenue growth takes total FY23 unaudited net revenue to date to $14.54m
• Strong growth underpinned by contributions from wholly-owned subsidiaries, including $1.85m in
revenue from Mernova Medicinal Inc.
• Health House International also delivered unaudited revenue of $4.851m, which included $2.99m in
net revenue from the division’s Australian operations
• Health House International’s Australian operations also generated an unaudited net profit of
$312,548 during Q3 FY23 - +10% profit margin reflects well-established operating procedures on
COGS (cost of goods sold) and a strong sales network across several leading Australian pharmacies
• Company remains focused on its stated strategy of delivering high revenue growth, while
maintaining a stringent control on costs to reach profitability